Early Morning Immune Checkpoint Blockade and Overall Survival of Patients with Metastatic Cancer: an In-depth Chronotherapeutic Study

Recent retrospective studies suggest potential large patient ’s benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment timing and patient survival, neoplastic response and toxicities was investigated, together with interactions with performance status (PS) and sex.

Source: European Journal of Cancer - January 22, 2024 Category: Cancer & Oncology Authors: Simona Catozzi, Souad Assaad, Lidia Delrieu, Bertrand Favier, Elise Dumas, Anne-Sophie Hamy, Aur élien Latouche, Hugo Crochet, Jean-Yves Blay, Jimmy Mullaert, Annabelle Ballesta, Pierre Heudel Tags: Original Research Source Type: research